8.5 months, suggesting a favorable trend. 286 These results indicate that stroma-directed therapies may require biomarker-based patient selection, and that patients with high hyaluronan levels are more likely to experience clinical benefit from improved drug delivery.
← all excerpts
Cancer-Associated Fibroblast-Targeted Nanomedicine in Solid Tumor Therapy: From Mechanisms of Therapeutic Resistance to Precision Stromal Modulation.
1
—
—